Welcure Drugs & Pharmaceuticals has made a series of significant announcements that are set to impact its share structure and capital base. The company's Board of Directors, in a meeting held on August 22, 2025, approved several key measures aimed at enhancing shareholder value and improving stock liquidity.

Stock Split

The pharmaceutical company has approved a 1:10 stock split, which will subdivide each existing equity share with a face value of ₹10 into ten equity shares with a face value of ₹1 each. This move is designed to make the company's shares more accessible to retail investors and potentially increase liquidity in the market.

Bonus Issue

In addition to the stock split, Welcure Drugs & Pharmaceuticals has also approved a bonus issue in the ratio of 1:10. This means shareholders will receive one bonus equity share for every ten equity shares held. The bonus shares will be issued by capitalizing the company's securities premium account, subject to shareholder approval.

Authorized Share Capital Increase

The Board has further approved an increase in the company's authorized share capital from ₹186.00 crore to ₹196.00 crore. This expansion in capital base provides the company with additional flexibility for future growth and capital raising initiatives.

Impact on Share Structure

The combined effect of these corporate actions will significantly alter Welcure's share structure:

Shareholder Approval and Implementation

These corporate actions are subject to shareholder approval, which the company plans to seek through a postal ballot. The record date for the sub-division of shares and the bonus issue will be announced after obtaining shareholder approval.

Welcure Drugs & Pharmaceuticals expects to complete the implementation of these corporate actions within approximately two months from the date of Board approval.

Market Impact

These strategic moves are expected to enhance the liquidity of Welcure's shares in the market. The stock split, in particular, aims to make the shares more affordable and accessible to a broader range of investors, potentially leading to increased trading activity.

Investors and market participants will be closely watching how these corporate actions unfold and their impact on Welcure Drugs & Pharmaceuticals' market performance in the coming months.

Welcure Drugs & Pharmaceuticals Ltd. has unveiled ambitious plans to establish an Agro-Pharma Research Laboratory, estimated to cost between ₹70-80 crore. The company also announced its intention to raise up to ₹80 crore through a Qualified Institutional Placement (QIP) to fund this initiative and for general corporate purposes.

Agro-Pharma Research Laboratory

The proposed laboratory will focus on converting agricultural and botanical inputs into pharma-grade products. Welcure Drugs aims to align the facility's design with current Good Manufacturing Practice (cGMP) standards and the U.S. Food and Drug Administration's (FDA) Botanical Drug Development guidance. This strategic move positions the company to potentially participate in broader international markets for botanical and ayurvedic products, subject to necessary approvals.

Market Opportunity

Welcure Drugs' initiative comes at a time of significant growth in the herbal and botanical medicine sector. According to industry sources cited in the company's disclosure:

These trends suggest a robust addressable market for compliant, evidence-based agro-derived therapeutics.

Funding Through QIP

To finance the Agro-Pharma Research Laboratory and for general corporate purposes, Welcure Drugs proposes to raise up to ₹80 crore through a Qualified Institutional Placement (QIP). The company plans to execute this fund-raise in one or more tranches, in accordance with SEBI regulations and other applicable laws.

Upcoming Board Meeting

A board meeting has been scheduled for August 28, 2025, to consider and potentially approve the QIP fund-raising proposal. The meeting will also address any necessary enabling resolutions, issue structure, and seek shareholders' approval as required.

Regulatory Compliance

Welcure Drugs has emphasized that the proposed project and fund-raise are subject to requisite board, shareholder, regulatory, and statutory approvals, as well as market conditions. The company has also confirmed that these proposals do not involve any related-party transactions.

In line with regulatory requirements, the trading window for the company's securities will remain closed until 48 hours after the announcement of the board meeting outcome.

As Welcure Drugs & Pharmaceuticals Ltd. embarks on this significant expansion into agro-pharma research, investors and industry observers will be keenly watching the developments that unfold following the upcoming board meeting.